<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02964936</url>
  </required_header>
  <id_info>
    <org_study_id>1517-CL-0314</org_study_id>
    <nct_id>NCT02964936</nct_id>
  </id_info>
  <brief_title>A Study of Intermittent Oral Dosing of ASP1517 in ESA-untreated Chronic Kidney Disease Patients With Anemia</brief_title>
  <official_title>ASP1517 Phase 3 Clinical Trial -A Multi-center, Randomized, 2-arm, Open-label Study of Intermittent Oral Dosing of ASP1517 for the Treatment of Anemia in ESA-untreated Chronic Kidney Disease Patients Not on Dialysis-</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>FibroGen</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the efficacy and the safety when ASP1517 is
      intermittently administered in Erythropoiesis Stimulating Agent (ESA)-untreated non-dialysis
      chronic kidney disease patients with anemia.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 11, 2017</start_date>
  <completion_date type="Anticipated">August 2018</completion_date>
  <primary_completion_date type="Anticipated">August 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hemoglobin (Hb) Response rate</measure>
    <time_frame>Up to Week 24</time_frame>
    <description>Hb response is defined as reaching target values for Hb and change of Hb from baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the average Hb from Week 18 to Week 24</measure>
    <time_frame>Baseline and Weeks 18 to 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number of subjects who achieve the target Hb level at the average of Week 18 to 24</measure>
    <time_frame>Weeks 18 to 24</time_frame>
    <description>Hb response defined as average Hb within the target range in this outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of rise in Hb (g/dL/week)</measure>
    <time_frame>Up to Week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of time points that each subject maintains the target Hb level</measure>
    <time_frame>Weeks 18 to 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number of subjects who achieves the target Hb level at each week</measure>
    <time_frame>Up to Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number of subjects who achieves the lower limit of the target Hb level</measure>
    <time_frame>Up to Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to achieve the lower limit of the target Hb level</measure>
    <time_frame>Up to Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Hb level at each week</measure>
    <time_frame>Baseline and Up to Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life assessed by EQ-5D-5L</measure>
    <time_frame>Up to Week 24</time_frame>
    <description>EQ-5D: EuroQol 5 Dimension 5 Levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life assessed by FACT-An</measure>
    <time_frame>Up to Week 24</time_frame>
    <description>FACT-An: Functional Assessment of Cancer Therapy-Anemia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with abnormal Vital signs and/or adverse events related to treatment</measure>
    <time_frame>Up to Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety assessed by body weight</measure>
    <time_frame>Up to Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety assessed by incidence of adverse events</measure>
    <time_frame>Up to Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety assessed by standard 12-lead electrocardiogram</measure>
    <time_frame>Up to Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with abnormal Laboratory values and/or adverse events related to treatment</measure>
    <time_frame>Up to Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration of unchanged ASP1517</measure>
    <time_frame>Up to Week 24</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Chronic Kidney Disease</condition>
  <arm_group>
    <arm_group_label>ASP1517 Low dose group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Study drug will be dosed three times weekly for 24 weeks and dose adjustments will be made during the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ASP1517 High dose group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Study drug will be dosed three times weekly for 24 weeks and dose adjustments will be made during the study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>roxadustat</intervention_name>
    <description>Oral administration</description>
    <arm_group_label>ASP1517 High dose group</arm_group_label>
    <arm_group_label>ASP1517 Low dose group</arm_group_label>
    <other_name>ASP1517</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects who were diagnosed with non-dialysis chronic kidney disease (CKD) and who are
             considered not to require renal replacement therapy during the study period

          -  Mean of the subject's two most recent Hb values before randomization during the
             Screening Period must be &lt;10.5 g/dL with an absolute difference ≤1.3 g/dL between the
             two values

          -  Either transferrin saturation ≥ 5% or serum ferritin ≥ 30 ng/mL

          -  Female subject must either:

        Be of non-childbearing potential:

          -  post-menopausal prior to pre-screening, or

          -  documented surgically sterile Or, if of childbearing potential,

          -  Agree not to try to become pregnant during the study after informed consent
             acquisition and for 28 days after the final study drug administration

          -  And have a negative urine pregnancy test at pre-screening

          -  And, if heterosexually active, agree to consistently use two forms of highly effective
             birth control (at least one of which must be a barrier method) starting at
             pre-screening and throughout the study period and for 28 days after the final study
             drug administration.

          -  Female subject must agree not to breastfeed starting at pre-screening and throughout
             the study period, and for 28 days after the final study drug administration.

          -  Female subject must not donate ova starting at pre-screening and throughout the study
             period, and for 28 days after the final study drug administration.

          -  Male subject and their female spouse/partners who are of childbearing potential must
             be using two forms of highly effective birth control (at least one of which must be a
             barrier method) starting at pre-screening and continue throughout the study period,
             and for 12 weeks after the final study drug administration

          -  Male subject must not donate sperm starting at pre-screening and throughout the study
             period, and for 12 weeks after the final study drug administration

        Exclusion Criteria:

          -  Concurrent retinal neovascular lesion requiring treatment and macular edema requiring
             treatment

          -  Concurrent autoimmune disease with inflammation that could impact erythropoiesis

          -  History of gastric/intestinal resection considered influential on the absorption of
             drugs in the gastrointestinal tract (excluding resection of gastric or colon polyps)
             or concurrent gastroparesis

          -  Uncontrolled hypertension

          -  Concurrent congestive heart failure (NYHA Class III or higher)

          -  History of hospitalization for treatment of stroke, myocardial infarction, or
             pulmonary embolism within 12 weeks before the pre-screening assessment

          -  Positive for hepatitis B surface antigen (HBsAg) or anti-hepatitis C virus (HCV)
             antibody at the pre-screening assessment, or positive for human immunodeficiency virus
             (HIV) in a past test

          -  Concurrent other form of anemia than renal anemia

          -  Having received treatment with ESA, protein anabolic hormone, testosterone enanthate,
             or mepitiostane within 6 weeks before the pre-screening assessment

          -  Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT) or total bilirubin
             that is greater than the criteria, or previous or concurrent another serious liver
             disease at pre-screening assessment

          -  Previous or current malignant tumor (no recurrence for at least 5 years is eligible.)

          -  Having undergone red blood transfusion and/or a surgical procedure considered to
             promote anemia within 4 weeks before the pre-screening assessment

          -  Having undergone a kidney transplantation

          -  History of serious drug allergy including anaphylactic shock

          -  Having a previous history of treatment with ASP1517

          -  Participation in another clinical study or post-marketing clinical study (including
             that of a medical device) within 12 weeks before informed consent acquisition
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Astellas Pharma Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site JP00007</name>
      <address>
        <city>Aichi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00018</name>
      <address>
        <city>Aichi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00028</name>
      <address>
        <city>Aichi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00001</name>
      <address>
        <city>Chiba</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00035</name>
      <address>
        <city>Ehime</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00012</name>
      <address>
        <city>Fukui</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00011</name>
      <address>
        <city>Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00031</name>
      <address>
        <city>Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00030</name>
      <address>
        <city>Hiroshima</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00034</name>
      <address>
        <city>Hiroshima</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00036</name>
      <address>
        <city>Hiroshima</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00005</name>
      <address>
        <city>Hokkaido</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00020</name>
      <address>
        <city>Hyogo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00015</name>
      <address>
        <city>Ibaraki</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00017</name>
      <address>
        <city>Ibaraki</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00021</name>
      <address>
        <city>Ibaraki</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00025</name>
      <address>
        <city>Ibaraki</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00037</name>
      <address>
        <city>Ibaraki</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00033</name>
      <address>
        <city>Ishikawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00029</name>
      <address>
        <city>Iwate</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00006</name>
      <address>
        <city>Kanagawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00014</name>
      <address>
        <city>Kanagawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00038</name>
      <address>
        <city>Kanagawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00010</name>
      <address>
        <city>Miyagi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00016</name>
      <address>
        <city>Nagano</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00024</name>
      <address>
        <city>Niigata</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00032</name>
      <address>
        <city>Oita</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00003</name>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00009</name>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00026</name>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00002</name>
      <address>
        <city>Saitama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00019</name>
      <address>
        <city>Saitama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00027</name>
      <address>
        <city>Saitama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00004</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00013</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00022</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00023</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00008</name>
      <address>
        <city>Toyama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 13, 2016</study_first_submitted>
  <study_first_submitted_qc>November 13, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 16, 2016</study_first_posted>
  <last_update_submitted>May 23, 2018</last_update_submitted>
  <last_update_submitted_qc>May 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Anemia</keyword>
  <keyword>Non-dialysis chronic kidney disease</keyword>
  <keyword>Roxadustat</keyword>
  <keyword>ASP1517</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

